Microvascular hyperpermeability that occurs at the level of the blood-brain barrier (BBB) often leads to vasogenic brain edema and elevated intracranial pressure following traumatic brain injury (TBI). At a cellular level, tight junction proteins (TJPs) between neighboring endothelial cells maintain the integrity of the BBB via TJ associated proteins particularly, zonula occludens-1 (ZO-1) that binds to the transmembrane TJPs and actin cytoskeleton intracellularly. The pro-inflammatory cytokine, interleukin-1β (IL-1β) as well as the proteolytic enzymes, matrix metalloproteinase-9 (MMP-9) are key mediators of trauma-associated brain edema. Recent studies indicate that melatonin a pineal hormone directly binds to MMP-9 and also might act as its endogenous inhibitor. We hypothesized that melatonin treatment will provide protection against TBI-induced BBB hyperpermeability via MMP-9 inhibition. Rat brain microvascular endothelial cells grown as monolayers were used as an in vitro model of the BBB and a mouse model of TBI using a controlled cortical impactor was used for all in vivo studies. IL-1β (10 ng/mL; 2 hours)-induced endothelial monolayer hyperpermeability was significantly attenuated by melatonin (10 μg/mL; 1 hour), GM6001 (broad spectrum MMP inhibitor; 10 μM; 1 hour), MMP-9 inhibitor-1 (MMP-9 specific inhibitor; 5 nM; 1 hour) or MMP-9 siRNA transfection (48 hours) in vitro. Melatonin and MMP-9 inhibitor-1 pretreatment attenuated IL-1β-induced MMP-9 activity, loss of ZO-1 junctional integrity and f-actin stress fiber formation. IL-1β treatment neither affected ZO-1 protein or mRNA expression or cell viability. Acute melatonin treatment attenuated BBB hyperpermeability in a mouse controlled cortical impact model of TBI in vivo. In conclusion, one of the protective effects of melatonin against BBB hyperpermeability occurs due to enhanced BBB integrity via MMP-9 inhibition. In addition, acute melatonin treatment provides protection against PLOS ONE |
Introduction
• Protective effects of melatonin against BBB breakdown induced by TBI in a mouse controlled cortical impact model of TBI in vivo.
Materials and Methods

Materials
Rat Brain Microvascular Endothelial Cells (RBMECs) and RBMEC Medium were obtained from Cell Applications Inc. (San Diego, CA). SensoLyte1 520 MMP-9 fluorometric Assay Kit was purchased from Anaspec Inc. (San Jose, CA). Transwell1-well plates were obtained from Corning Costar (New York, USA). Nunc Lab Tek II-CC, 8-well glass chamber slides, Interleukin-1β human, melatonin, fibronectin from bovine plasma, β-actin, albumin from bovine serum, Evans blue, trichloroacetic acid and fluorescein isothiocyanate-dextran-10 kDa were purchased from Sigma Aldrich (St. Louis, MO). Rabbit anti ZO-1 (Cat # 617300), mouse anti ZO-1 (Cat # 339100), 0.25% Trypsin (1X), Opti-MEM (1X)/reduced serum medium, Dulbecco's modified Eagle's medium (DMEM; with high glucose, HEPES, no phenol red (1X)), NuPAGE Novex1 10% Bis-Tris protein gels, NuPAGE1 MOPS SDS Running Buffer, NuPAGE1 Transfer Buffer, HyClone Dulbecco's phosphate buffered saline (PBS, without calcium, magnesium, or phenol red), TRIzol1 Reagent, SuperScript1 IV First-Strand Synthesis System, Halt1 Protease Inhibitor Cocktail (100X), Pierce™ ECL Western Blotting substrate and rhodamine phalloidin were purchased from Thermo Fisher Scientific (Carlsbad, CA). Anti-MMP-9 antibody (cat # ab-3) was obtained from EMD Millipore (Billerica, MA). Goat anti-mouse IgG-HRP and donkey anti-rabbit IgG-FITC secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). EZViable™ Calcein AM Cell Viability fluorometric assay kit was bought from Biovision (Milpitas, CA). We also purchased Vector VECTASHIELD1 Mounting Media with DAPI from Vector Laboratories (Burlingame, CA). Pierce™ BCA Protein Assay Kit and RT 2 qPCR Primer Assay for Mouse GAPDH were purchased from Qiagen (Valencia, CA). GM6001 (also called as Ilomastat or Galardin) and MMP-9 inhibitor 1 were purchased from Calbiochem (Billerica, MA). Cell Lysis Buffer (10X) was bought from Cell Signaling Technology, Inc. (Danvers, MA). Primers were purchased from Thermo Fisher Scientific (Carlsbad, CA). MMP-9 siRNA and control siRNA (ON-TARGETplus siRNA) were purchased from Dharmacon, General Electric (Pittsburgh, PA).
Cell culture
Primary cultures of RBMECs derived from the brain of adult Sprague Dawley rats were purchased from the Cell Applications Inc. (San Diego, CA). RBMECs were initially grown on 0.05% fibronectin-coated cell culture dishes, using the RBMEC medium in a cell culture incubator (95% O 2 , 5% CO 2 at 37°C). Endothelial cells were treated with 0.25% trypsin-EDTA for cell detachment. Detached cells were then grown on fibronectin-coated Transwell1 inserts, chamber slides or 100 mm dishes for experimental purposes. RBMEC passages 8-10 were chosen for all the experiments.
Animals and surgeries
C57BL/6 mice (25-30 g) were purchased from Charles River Laboratories (Wilmington, MA). Animals were maintained at the Texas A&M University Health Science Center College of Medicine and Baylor Scott and White Health animal facility on a 12:12 hour dark/light cycle, with free access to food and water. The room temperature was maintained at 25°± 2°C. Surgical and experimental procedures used in this study were conducted after approval from the Baylor Scott and White Health/Texas A&M University Health Science Center College of Medicine Institutional Animal Care and Use Committee. The facility is approved by the Association for Assessment and Accreditation of Laboratory Animal Care International in accordance with the National Institutes of Health guidelines. The animals were anesthetized with urethane, i.p. injection (2 mL/kg body weight) and was continuously observed by an investigator till the end of the study (up to one hour following traumatic brain injury). Our studies show that at this dose of urethane, animals are under deep anesthesia and has minimized any animal suffering. One-hour post-injury, animals were transcardially perfused with sterile saline containing heparin (1000 U/mL) for at least 20 minutes. This was not a survival study and no unexpected animal death was observed. The details of surgical procedures and the associated studies are described in detail in various sections below: Craniotomy Procedure. The head of the animal was shaven and the surgical site on the surface of the head was cleaned with an alcohol wipe. Lubricating ointment was applied to the eyes. Midline incision on the scalp helps to remove the skin from top of the skull exposing the sagittal suture, bregma and lambda. A circular craniotomy window, 3-4 mm in diameter was made on ipsilateral hemisphere, between lambda and bregma using a microdrill. The resulting bone flap was removed. Sham animals received only craniotomy surgery, while TBI injury group received brain injury via controlled cortical impactor following craniotomy procedure.
Controlled cortical impactor and TBI. These studies employ Benchmark™ Stereotaxic Impactor from Leica, for inflicting TBI in mice. Following craniotomy procedure, the animals were mounted on the stereotaxic frame. An impactor probe of 3 mm diameter was used to impact the exposed part of the brain. The depth of the injury was used to determine the severity of the injury. Settings for mild TBI used in this study are: 2 millimeters depth, 0.5 meters/second velocity and 100 milliseconds contact time as described in Chen et al, 2014 [17] .
Treatments
Melatonin at a dose of 10 mg/kg was used for the acute drug administration studies. This dose was chosen based on the studies done in mouse model of TBI [18] . Melatonin was administered via the tail vein along with Evans blue injection and allowed to circulate for 30 minutes prior to TBI.
Brain endothelial monolayer permeability in vitro
RBMECs were grown on fibronectin-coated Transwell1 inserts as monolayers for 72-96 hours and regularly checked for confluency. Monolayers were initially exposed to phenol red free DMEM for 45 minutes to an hour. DMEM treated cells were then treated with various concentrations of IL-1β (1-100 ng/mL) for 2 hours (Panel 1A) or IL-1β (10 ng/mL) treatment at various time points (1-4 hours; Panel 1B). At the end of the treatment, FITC labeled dextran-10 kDa (5 mg/mL; 30 minutes) was applied to the luminal compartment. One hundred microliters of sample was collected from the abluminal compartment at the end of 30 minutes and measured fluorometrically at 485/520 nm (Excitation/Emission) using Fluoroskan Ascent™ FL Microplate Fluorometer and Luminometer (Vantaa, Finland). These studies provided information on the minimal dose and time exposure of IL-1β to induce BBB endothelial cell hyperpermeability.
Using the above information, a separate set of experiments were conducted to study the effect of GM6001 (broad-spectrum MMP inhibitor; 10 μM; 1 hour; Panel 2A), MMP-9 inhibitor 1 (MMP-9 specific inhibitor; 5 nM; 1 hour; Panel 2B) and melatonin (10 μg/mL; 1 hour; Panel 2C) pretreatment on IL-1β (10 ng/mL; 2 hours) treatment-induced monolayer hyperpermeability. At the end of the experiment, FITC-dextran-10 kDa was added to the donor chamber and fluorescence intensity measurements were performed as described above.
Melatonin dose and time exposure were chosen from the studies done in our lab in burn trauma models [16] . MMP-9 inhibitor 1 used in these studies is a cell-permeable, potent, selective and reversible MMP-9 inhibitor with IC 50 at 5 nM for MMP-9 inhibition. It inhibits other MMPs at concentrations higher or lower than 5 nM, hence 5 nM was specifically chosen for these studies. MMP-9 inhibitor 1 concentration chosen is also supported by the studies done in our lab to study the effect of TNF-α on BBB hyperpermeability [14] . The dose and exposure time for GM6001 were obtained from Simao et al, 2012 [19] .
Untreated cells served as control. Each experiment was performed once and then repeated four or six times. Fluorescence intensity values were plotted on the Y-axis and represented as % control. Data were expressed as mean ± % SEM and statistical differences among groups were determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences between specific groups. A value of p<0.05 was considered statistically significant.
Monolayer transfection studies
RBMECs were grown on fibronectin-coated Transwell1 inserts for 24 hours and treated with control siRNA or MMP-9 siRNA at a concentration of 25 nM for 48 hours. Transfection was performed according to manufacturer's instructions. Transfected monolayers were then exposed to IL-1β (10 ng/mL; 2 hours; Fig 3) and permeability was determined based on the leakage of FITC-dextran-10 kDa (5 mg/mL; 30 minutes) leakage from the luminal to the abluminal chamber. One hundred microliters of the sample was obtained from the abluminal chamber and fluorescence intensity was measured at 485/520 nm (Excitation/Emission) using Fluoroskan Ascent™ FL Microplate Fluorometer and Luminometer.
Untreated or control siRNA transfected cells were used as control. Each experiment was performed once and then repeated four times. Fluorescence intensity was plotted on the Y-axis and represented as % control. Data were expressed as mean ± % SEM and statistical differences among groups were determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences between specific groups. A value of p<0.05 was considered statistically significant. In order to determine the efficiency of knockdown, total proteins from control siRNA or MMP-9 siRNA transfected cells were subjected to PAGE and immunoblot analysis of MMP-9 protein followed by its quantitative measurement by using ImageJ software.
Measurement of MMP-9 activity
A SensoLyte1 520 MMP-9 fluorometric Assay Kit was employed to measure the MMP-9 activity in the cells. This kit detects the MMP-9 activity in samples by using a 5-carboxyfluorescein Ser-Leu-Gly-Arg-Lys-Ile-Gln-Ile-Gln-Lys(QXL1520)-NH2 (5-FAM/ QXL™ 520 fluorescence resonance energy transfer (FRET) peptide). In intact FRET peptide, the fluorescence of 5-FAM is quenched by the QXL™ 520. However, on cleavage of the peptide by MMP-9 fluorescence is recovered and measured at 490/520 nm (Excitation/Emission).
In this procedure, RBMECs were grown in petri dishes until confluency is achieved. Cells were then pretreated with MMP-9 inhibitor 1 (5 nM; 1 hour; Panel 4A) or melatonin (10 μg/ mL; 1 hour) followed by IL-1β (10 ng/mL; 2 hours; Panel 4B). At the end of the experiment, cells were washed twice in PBS and exposed to the assay buffer provided in the kit. Cells were then scraped and the cell lysates were collected. Cell lysates were briefly sonicated and centrifuged in order to collect supernatants. Supernatants were used to measure the MMP-9 activity in the cells. Equal amounts of proteins were taken in each well and 4-aminophenylmercuric acetate (APMA) was added to samples and incubated for 2 hours in dark; in order to activate the pro-MMPs. To the activated samples, MMP-9 substrate, 5-FAM/QXL 520 FRET peptide was added and incubated for another 30 minutes in dark and read fluorometrically at 490/520 nm (Excitation/Emission).
Untreated cells served as control. Each experiment was performed once and then repeated four times. MMP-9 activity was expressed as relative fluorescence units (RFU) and plotted on the Y-axis. Data were expressed as mean ± SEM and statistical differences among groups were determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences between specific groups. A p value of <0.05 was considered statistically significant.
ZO-1 immunofluorescence and rhodamine phalloidin labeling for f-actin
Zonula occludens-1 junctional localization and f-actin stress fibers were assessed using immunofluorescence and rhodamine phalloidin labeling techniques respectively. RBMECs were grown on the chamber slides for overnight. Cells were initially exposed to Opti-MEM/reduced serum medium, followed by pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour; Panel 5A) and melatonin (10 μg/mL; 1 hour; Panel 5B) and subsequently with IL-1β (10 ng/mL; 2 hours) treatment. Cells were then fixed in 4% paraformaldehyde in PBS for 10-15 minutes and permeabilized in 0.5% Triton-X 100 in PBS for another 10-15 minutes. Cells were blocked using 2% bovine serum albumin (BSA) in PBS for an hour at room temperature. Cells were then incubated overnight in anti-rabbit primary antibodies against ZO-1 (#617300; 1:150) in 2% BSA-PBS, followed by incubation with anti-rabbit IgG-FITC conjugated secondary antibody for an hour at room temperature. Cells were then washed and mounted using VECTA-SHEILD1 Antifade Mounting Media with DAPI for nuclear staining.
For rhodamine phalloidin labeling, treatments were performed in the same way as for ZO-1 immunofluorescence study. Following treatments, cells were fixed, permeabilized, and blocked in 2% BSA-PBS as described earlier. Cells were then labeled with rhodamine phalloidin (1:50) in 2% BSA-PBS for 20 minutes (Fig 6, Panels A and B) . Chamber slides were then washed and mounted using VECTASHIELD1 Antifade Mounting Media with DAPI for nuclear staining. Cells were visualized and scanned at a single optical plane with an Olympus Fluoview 300 Confocal Microscope (Center Valley, PA), with a PLA PO 60X water immersion objective. Untreated cells served as control.
Real Time-PCR studies
RBMECs were grown on 100 mm cell culture dishes until 80-90% confluency was reached. Cells were then pretreated with MMP-9 inhibitor 1 (5 nM; 1 hour) followed by IL-1β (10 ng/ mL; 2 hours) (Fig 7; Panels A and B) . Following treatments, cells were washed thrice in PBS and total RNA was then extracted using TRIzol1 reagent according to the manufacturer's instructions. RNA concentration and quality were determined by employing the ratio of absorbance at 260/280 nm using Biotek Synergy Hybrid Spectrophotometer (Winooski, VT). Reverse transcription was performed using the SuperScript1 IV First-Strand Synthesis System. Quantitative real time PCR was performed using the RT 2 using Stratagene Mx3000P qPCR System, Agilent Technologies (La Jolla, CA), using 1 μL of cDNA for 10 minutes at 95°C, followed by 40 cycles of 15 sec at 95°C for denaturation and 1 min at 60°C for annealing. Relative abundances of target genes were calculated by normalizing Ct values to endogenous control glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Cells were treated with IL-1β, while untreated cells served as control. Each experiment was repeated three times. Relative gene expression of ZO-1 was obtained by normalizing the C t values to the endogenous control GAPDH for each repeat. Normalized C t values were expressed as mean ± SEM. Statistical differences among groups were determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences between specific groups. A p value of <0.05 was considered statistically significant.
Western blot analysis of ZO-1
Western blots were performed to determine the potential changes in ZO-1 protein expression. Cells were initially exposed to reduced serum medium followed by IL-1β (10 ng/mL; 2 hours) treatment. At the end of the study, cells were washed twice in ice-cold PBS and incubated in ice-cold cell lysis buffer (1X) along with protease inhibitor cocktail (1X) for 5 minutes in cell culture dishes. Cells were then scraped, sonicated and centrifuged at 14,000g for 10 minutes at 4°C. Supernatant was collected from the extracts and protein concentration was determined using protein assay kit. Equal amounts of total protein (50 μg) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% Bis-Tris precast gels at constant voltage (145 V) for 180 minutes. Proteins were then transferred onto the nitrocellulose membrane at constant voltage (30 V) for overnight and the membranes were blocked using 5% nonfat dry milk in Tris-Buffered Saline (TBS) with 0.05% Tween-20 and subsequently incubated with primary mouse monoclonal anti ZO-1 antibody (1:250 dilution). Membranes were washed thrice in TBS-T and incubated with the goat anti-mouse IgG-HRP conjugated secondary antibody. After washing, the immunoblots were visualized by ECL Western Blotting Substrate. Untreated cells served as control. Equal amount of protein sample loading was verified by assessing β-actin protein expression.
Cell viability studies
In order to determine if the changes in permeability was due to the loss of cell viability or not, a cell viability assay was conducted. An EZViable™ Calcein AM Cell Viability Assay Kit (Fluorometric) was used for quantify the number of viable cells. Calcein AM is a non-fluorescent, hydrophobic compound that easily penetrates intact and live cells. Hydrolysis of the calcein AM by intracellular esterase produces a hydrophilic, strongly fluorescent compound that is retained in the cell cytoplasm, which can be measured at 485/530 nm (Excitation/Emission).
Equal numbers of cells were grown on sterile black 96 well trays. On reaching confluency, growth media is discarded and cells were washed in PBS and pre-exposed to phenol red-free medium for 1 hour. Cells were divided into control (untreated) and IL-1β ss(10 ng/mL) treatment groups. Hydrogen peroxide at 100 mM was used as a positive control. Following treatments, cells were then exposed to calcein buffer solution (calcein AM: calcein dilution buffer in 1:500 dilution) and incubated at 37°C for 30 minutes and a fluorometric reading was obtained.
Fluorescence intensity was plotted on the Y-axis and represented as % control. Data were expressed as mean ± % SEM and statistical differences among groups were determined by oneway analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences between specific groups. A p value of <0.05 was considered statistically significant.
Evans blue leakage studies
Evans blue dye binds to the albumin in the blood enabling us to detect the vascular leakage into the extravascular tissue following TBI. C57BL/6 mice (25-30 g) were anesthetized with urethane, i.p. injection (2 mL/kg body weight) followed by Evans blue dye, i.v. injection (2% wt/ vol in saline; 4 mL/kg body weight). Melatonin was injected at a concentration of 10 μg per gram body weight of the animal. A stock of 50μg/μL of 100% alcohol was prepared. Melatonin from the stock concentration was then diluted in Evans blue, based on the body weight of the animal. The total alcohol concentration was less than 0.5% of the total blood volume. Evans blue was allowed to circulate in the animal for 30 minutes prior to performing sham surgery (only craniotomy) or TBI using controlled cortical impactor. Drugs were given to the animal along with Evans blue injection and allowed to circulate for 30 minutes as well. Settings for mild TBI are described in the CCI procedure.
Animals were grouped into Sham (only craniotomy; n = 6), Vehicle + Sham (75% ethanol injection followed by craniotomy; n = 6), Vehicle + TBI group (75% ethanol followed by mild TBI; n = 5), and melatonin +TBI group (melatonin [10 μg/gram body weight of the animal] injection followed by mild TBI; n = 6). The vehicle was combined with Evans Blue when given and the total alcohol concentration was less than 0.5% of the total blood volume.
One-hour post-TBI, animals were transcardially perfused with sterile saline containing heparin (1000 U/mL) for at least 20 minutes. Brains were extracted and brain cortex was carefully separated and weighed. Brain cortices were then homogenized in 1 mL of 50% (wt/vol) trichloroacetic acid (TCA) in saline. Homogenate was then centrifuged at 6,000g for 20 minutes at 4°C. Supernatants were extracted and further diluted in 3 parts of ethanol (1:3; 50% TCA: 95% ethanol). Samples were then quantitated fluorometrically at 620/ 680 nm (Excitation/Emission) using Biotek Synergy Hybrid H1 spectrophotometer (Winooski, VT). Evans blue concentration in the samples were evaluated using external standards for Evans blue ranging from 50-1000 ng/mL, prepared in same solvent (1:3; TCA: 95% ethanol). Evans blue amount in the samples was expressed as ng/ brain cortex ± SEM. Statistical differences among groups were determined by one-way analysis of variance (ANOVA) followed by Bonferroni post hoc test to determine significant differences between specific groups. A p value of <0.05 was considered statistically significant.
Statistical Analysis
Data are expressed as the mean ± % SEM for the monolayer permeability, monolayer transfection and cell viability studies; while mean ± SEM is employed for data obtained from MMP-9 activity assay, real time-PCR studies and Evans blue leakage studies. Statistical differences among groups were determined by one-way ANOVA followed by Bonferroni post hoc test to determine significant differences between specific groups. Student's t-test was employed for comparing the protein expression data. p<0.05 was considered a statistically significant difference.
Results
IL-1β treatment induces BBB endothelial cell monolayer hyperpermeability
Endothelial cell monolayers were pretreated with various concentrations of IL-1β ranging from 1-100 ng/mL for a 2-hour period. Results from this study confirmed that IL-1β treatment at 10 ng/mL for 2 hours was found to be the minimal dose to induce monolayer hyperpermeability (Fig 1; Panel A; p <0.05) .
In a separate set of experiments, RBMECs were then treated with IL-1β (10 ng/mL) for various time periods ranging from 1 to 4 hours. Result from this study further confirmed that IL-1β treatment (10 ng/mL; 2 hours) was the minimal dose to induce RBMEC monolayer hyperpermeability (Fig 1; Panel B ; p <0.05). Hence, IL-1β treatment at 10 ng/mL dose for a 2-hour period was used to induce monolayer hyperpermeability in the following experiments.
MMP-9 specific inhibition attenuates IL-1β-induced BBB endothelial cell hyperpermeability
Initial preliminary studies to confirm the involvement of MMPs in mediating IL-1β-induced monolayer hyperpermeability; GM6001 (broad-spectrum MMP inhibitor) was used. Endothelial cell monolayers were pretreated with GM6001 (Fig 2; Panel A; 10 μM; 1 hour) followed by IL-1β (10 ng /mL; 2 hours).
To study the effect of MMP-9 specific inhibition, MMP-9 inhibitor 1 and melatonin were employed. IL-1β (10 ng/mL; 2 hours) treatment-induced monolayer hyperpermeability was significantly attenuated on pretreatment with MMP-9 inhibitor 1 (Fig 2; Panel B; 5 nM; 1 hour) and melatonin (Fig 2; Panel C; 10 μg/mL; 1 hour). Permeability was assessed by monolayer permeability assays as described earlier.
MMP-9 knockdown attenuates IL-1β-induced endothelial cell hyperpermeability
Significant contribution of MMP-9 in attenuating IL-1β-induced endothelial cell hyperpermeability is further supported by siRNA transfection studies. IL-1β (10 ng/mL; 2 hours) treatment to MMP-9 knockdown (25 nM; 48 hours) cells significantly reduced IL-1β treatment-induced monolayer hyperpermeability (Fig 3) . siRNA treated groups were compared to the control siRNA group, while the IL-1β alone treated group was compared to the control group.
Immunoblot analysis of MMP-9 protein following transfection of the cells with control siRNA or MMP-9 siRNA showed a 37% decrease in MMP-9 levels. This decrease was statistically insignificant (Student's t-test; S1 Fig) . IL-1β treatment-induced MMP-9 activity is attenuated by pretreatment with MMP-9 inhibitor 1 and melatonin IL-1β treatment significantly increased MMP-9 activity in RBMECs, while pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour) or melatonin (10 μg/mL; 1 hour) significantly attenuated IL-1β (10 ng/mL; 2 hours) treatment-induced MMP-9 activity (Fig 4; Panels A and B) . MMP-9 activity measurements were performed as described in the methods section. MMP-9 inhibitor 1 was used as a pharmacological inhibitor of MMP-9; however, anti-MMP-9 properties of melatonin are still not as well-established. Our studies support the role of melatonin as a potential MMP-9 inhibitor. Fig 2. GM6001, MMP-9 inhibitor 1 and melatonin pretreatment attenuates IL-1β treatment-induced monolayer hyperpermeability. Panel A indicates the effect of GM6001 (broad-spectrum MMP inhibitor; n = 4); while Panels B and C employ MMP-9 specific inhibitors: MMP-9 inhibitor 1 (n = 4) and melatonin (n = 6) pretreatment on IL-1β (10 ng/mL; 2 hours)-induced monolayer hyperpermeability. Monolayer permeability is expressed as a percentage control of FITC-dextran-10 kDa fluorescence intensity, plotted on the Y-axis. Data are expressed as mean ± % SEM. '*a' indicates significant increase compared to control group; '*b' indicates significant decrease compared to the IL-1β treated group. p<0.05 was considered statistically significant. Melatonin and MMP-9 inhibitor 1 provides protection against IL-1β treatment-induced loss of ZO-1 junctional integrity Cells were processed for immunofluorescence localization of tight junction protein, ZO-1. IL-1β (10 ng/mL; 2 hours) treatment-induced ZO-1 junctional discontinuity (white arrows; Panel 5A and B) compared to the control cells (Fig 5) . Pretreatment with MMP-9 inhibitor 1 (5 nM; 1 hour) and melatonin (10 μg/mL; 1 hour) decreased IL-1β treatment-induced ZO-1 junction integrity (Fig 5) . Untreated cells served as control. These studies support that IL-1β treatment-induced monolayer hyperpermeability occurs via ZO-1 junctional disruption and possibly by ZO-1 redistribution.
Melatonin and MMP-9 inhibitor 1 provides protection against IL-1β treatment-induced f-actin stress fiber formation For assessing the cytoskeletal assembly, rhodamine phalloidin labeling technique was performed. Untreated cells served as control. IL-1β treatment-induced f-actin stress fiber formation (white arrows; Fig 6; Panels A and B) was reduced on pretreatment with MMP-9 inhibitor 1 and melatonin.
IL-1β treatment neither induces ZO-1 mRNA expression nor alters ZO-1 protein expression IL-1β treatment (10 ng/mL; 2 hours) did not alter ZO-1 or MMP-9 mRNA expression by RT-PCR studies (Fig 7; Panels A and B) . IL-1β treatment (10 ng/mL; 2 hours) did not the alter ZO-1 protein expression (Fig 7; Panel C) .
IL-1β treatment does not induce cell death in endothelial cells
IL-1β treatment at 10 ng/mL for 2 hours did not cause any significant change in cell viability (Fig 8) . Hydrogen peroxide at 100 mM concentration for 2 hours was used as a positive control. Hydrogen peroxide significantly attenuated cell viability compared to untreated control group (p <0.05).
Melatonin pretreatment attenuates TBI-induced BBB hyperpermeability
Mice subjected to TBI demonstrated significant increase in Evans blue leakage compared to the sham animals. Evans blue extravasation was performed using ipsilateral brain cortices. Pretreatment with melatonin attenuated mild TBI-induced Evans blue leakage into the brain tissue (Fig 9; Panels A and B) . Evans blue leakage was assessed fluorometrically at 620/680 nm (Excitation/Emission). This study suggests that melatonin can be used as a potential therapeutic agent in attenuating BBB hyperpermeability that occurs following TBI.
Discussion
The results from this study demonstrate that melatonin has protective effects against IL-1β-induced BBB dysfunction and hyperpermeability in vitro via MMP-9 inhibition and by maintaining tight junctional and cytoskeletal integrity. It also effectively decreases acute BBB hyperpermeability in a mouse controlled cortical impact model of traumatic brain injury in vivo. Furthermore, the results show that IL-1β-induced acute barrier dysfunctions are not due to alterations in endothelial cell viability or a decrease in the content or expression of the key tight junction associated protein ZO-1. Matrix metalloproteinases (MMPs) are zinc and calcium proteases that play several roles in vascular physiology and pathophysiology [16, 20, 21] . Matrix metalloproteinase-9 levels are found to increase significantly in the cerebrospinal fluid (CSF) samples of the traumatic brain injury patients [11] . Identification of MMP-9 in the CSF may indicate their role in BBB disruption, which is supported by its ability to degrade various tight junction proteins such as claudin-5, occludin, and zonula occludens (ZO-1) in cultured brain endothelial cells [12] . Although studies done in intracerebral hemorrhagic (ICH) models suggest that IL-1β may induce MMP-9 activation and subsequent ZO-1 disruption [13] , no elaborate studies have been done to imply its significance in regulating BBB dysfunction and hyperpermeability. Our studies further employ various MMP inhibitors like GM6001, MMP-9 inhibitor 1 and melatonin, in order to study the effect of MMP-9 inhibition on IL-1β-induced BBB dysfunction and hyperpermeability.
Interleukin-1β upregulation is also observed following experimental brain injuries [13, 22] and it has been attributed to several of the adverse consequences of traumatic brain injury. Our studies support the contribution of IL-1β in inducing BBB dysfunction and hyperpermeability as demonstrated in our in vitro permeability studies, changes in ZO-1 junctional localization, and f-actin stress fiber formation. Although, IL-1β treatment induced ZO-1 junctional disruption and BBB hyperpermeability, no change in the total ZO-1 protein or gene expression was observed. These studies indicate a possibility that IL-1β treatment-induced alterations in the BBB may not be due to changes at the gene or protein level but could be due to displacement of ZO-1 from the tight junctions thus detaching itself from the transmembrane tight junction as well as the actin cytoskeleton. Cytoskeletal changes in the form of increased actin stress fibers, observed in our studies following IL-1β treatment parallel the alterations in monolayer permeability and barrier dysfunctions. Recent studies demonstrate that actin stress fiber formation is not necessarily connected to increase in permeability, but might actually reflect a cellular response to repair disrupted barrier function [23, 24] . Our observation thus, suggest that the barrier is undergoing repair process and the hyperpermeability observed may be reversible. The involvement of other intermediate signaling pathways that are activated by mitogen activated protein kinases like c-Jun N-terminal kinases (JNK) and p38 as described previously, are also possible [3, 25] .
IL-1β treatment induces MMP-9 activity in brain endothelial cells in vitro and one of the mechanisms by which MMP-9 inhibitor 1 and melatonin pretreatment attenuates IL-1β-induced MMP-9 activity may occur by direct binding of MMP-9 inhibitor 1 and melatonin to MMP-9. However, these studies need to be explored further in order to understand how MMP-9 inhibitors inhibit IL-1β-induced BBB hyperpermeability. As MMP-9 is indicated to activate protein kinase C via extracellular signal-regulated kinases (ERK) in TBI [26] , this can be a potential mechanism that needs further studies.
Our cell culture studies employ commercially available primary cultures of microvascular endothelial cells isolated from rat brain. They are then cultured continuously for the purpose of the experiment upto 8-10 passages. Although they are most representative to the in vivo experimental models, they suffer from various limitations like relative short life span, susceptibility to contamination and may not also fully act like a tissue due to the complexity of the media apart from the fact that there is considerable variation in population and between preparations. These finite cell lines also tend to differentiate over a period of time and the culture tends to select for aberrant cells.
The present study employed pharmacological and endogenous MMP-9 inhibitors i.e. MMP-9 inhibitor 1 and melatonin in order to test their effect on IL-1β treatment-induced BBB dysfunction and hyperpermeability. Use of melatonin has great advantage as it can cross the BBB due to its lipophilic nature and can act as a neuroprotectant [27] ; apart from the fact that is a relatively less expensive drug that is available over-the-counter with no known adverse effects. Our results underline the need for future studies to explore the therapeutic advantages of melatonin against BBB dysfunction and edema formation following TBI. Our studies, while supporting the recent observation that melatonin is protective against brain edema and elevated ICP in a rat weight drop model of TBI [28] , further shows how it works in an acute setting and also its potential mechanisms of action at the level of the tight junctions of the bloodbrain barrier.
Although these results support the role of melatonin in regulating BBB endothelial functions via MMP-9 inhibition, we do not believe its contribution is only owing to its MMP-9 inhibitory properties and there is a need to explore other possible mechanisms. Future studies should aim to address the effect of melatonin on 1) tissue inhibitors of MMPs (TIMPs), 2) transcription factors responsible for MMP-9 expression such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator protein (AP-1), as suggested by Grossetete et al (2009) [11] , 3) on various ERK MAPK and 4) phosphorylation status of the tight junctions.
In conclusion, the preset study demonstrates that melatonin has protective effects against acute IL-1β-induced BBB dysfunction and hyperpermeability via MMP-9 inhibition and by preserving tight junction integrity in vitro. The protective effects of melatonin in an acute setting in vitro parallel with its protective effects against TBI in a controlled cortical impact model of TBI in vivo and provide great promise to early regulation of secondary injuries.
Supporting Information S1 Fig. Immunoblot analysis of MMP-9 demonstrating an insignificant reduction in MMP-9 protein following MMP-9 siRNA transfection in RBMECs compared with control siRNA group. A. Representative bands from immunoblot analysis. B. Analysis of the data using ImageJ (Student's t-test; p>0.05). The data is expressed as relative expression of MMP-9 to β-Actin. (TIF)
